{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-010951","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2022-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.496386+00:00","generated_at":"2026-06-26T21:42:01.752074+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Aeglea Bio's VP/Controller Steven Weber resigns; CFO Alspaugh named principal accounting officer","bullets":["Steven Weber resigns as VP/Corporate Controller and principal accounting officer, effective March 25, 2022.","CFO Jonathan Alspaugh appointed principal accounting officer effective March 17, 2022.","Alspaugh, age 39, has served as CFO since July 2021; prior roles include Managing Director at Evercore."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-010951","json":"https://secwatch.observer/filing/0001564590-22-010951.json","markdown":"https://secwatch.observer/filing/0001564590-22-010951.md","text":"https://secwatch.observer/filing/0001564590-22-010951.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000156459022010951/0001564590-22-010951-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000156459022010951/agle-8k_20220316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:42:01.752074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"229d97a73a","claim":"Steven Weber resigned as Vice President and Corporate Controller at Spyre Therapeutics, Inc..","evidence_excerpt":"On March 16, 2022, Steven Weber, the Vice President and Corporate Controller of Aeglea Biotherapeutics, Inc. (the “Company”), and the Company’s principal accounting officer, notified the Company that he will be resigning from his positions, effective March 25, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000156459022010951/0001564590-22-010951-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Vice President and Corporate Controller"}],"fact_type":"executive_change"},{"claim_id":"793476e11e","claim":"Jonathan Alspaugh was appointed as Principal Accounting Officer at Spyre Therapeutics, Inc..","evidence_excerpt":"On March 17, 2022, the Company appointed Jonathan Alspaugh, age 39, Chief Financial Officer, as its principal accounting officer, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000156459022010951/0001564590-22-010951-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}